journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Neurotherapeutics

journal
https://www.readbyqxmd.com/read/29027821/it-is-dopey-to-stop-giving-dopamine-to-hospitalized-patients-with-parkinson-s-disease
#1
Jason Margolesky, Carlos Singer
No abstract text is available yet for this article.
October 13, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/29023182/potential-clinical-utility-of-multiple-system-atrophy-biomarkers
#2
Kurt A Jellinger
Multiple system atrophy (MSA), an adult-onset, fatal disorder of uncertain aetiology, characterized by parkinsonism, cerebellar, autonomic and motor dysfunctions, is an α-synucleinopathy with glioneuronal degeneration involving multiple parts of the nervous system. The clinical variants correlate with the morphological phenotypes of striatonigral degeneration (MSA-P), olivoponto-cerebellar atrophy (MSA-C), and mixed type MSA. Neuropathological hallmark is the deposition of aberrant α-synuclein in glia and neurons forming cytoplasmic inclusions that cause cell dysfunction/demise...
October 12, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28971695/valbenazine-for-the-treatment-of-tardive-dyskinesia
#3
Thomas Müller
Introduction Chronic intake of typical neuroleptics or centrally acting dopamine receptor blocking antiemetics may cause onset of tardive syndromes. Various types exist. One of them is tardive dyskinesia, characterised by often stigmatising, purposeless, rapid, repetitive, stereotypic, involuntary movements of face, limbs or trunk. Effective symptomatic drug treatment options beyond application of tetrabenazine are rare. Tetrabenazine is usually administered three times daily due to the short half life of this agent...
October 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28949252/pharmacological-therapies-for-pain-in-parkinson-s-disease-a-review-paper
#4
Abdul Qayyum Rana, Danial Qureshi, Walid Sabeh, Abdullah Mosabbir, Eraad Rahman, Zainab Sarfraz, Ruqqiyah Rana
No abstract text is available yet for this article.
September 26, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28918666/treatment-options-for-severe-traumatic-brain-injuries-in-children-current-therapies-challenges-and-future-prospects
#5
Lisa A DelSignore, Robert C Tasker
Severe traumatic brain injury (TBI) afflicts many children and adults worldwide, resulting in high rates of morbidity and mortality. Recent therapeutic advances have focused on both surgical and medical treatment options, but none have been proven to reduce overall morbidity and mortality in this population. Areas covered: Several emerging therapies are addressed that focus on treating related secondary injuries and other clinical sequelae post-TBI during the acute injury phase (defined by authors as up to four weeks post-injury)...
September 22, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28877611/an-update-on-behavioral-treatments-in-migraine-current-knowledge-and-future-options
#6
Peter Kropp, Bianca Meyer, Wolfgang Meyer, Thomas Dresler
Besides pharmacological and interventional treatments a variety of non-medical therapeutic options exist for migraine, which has largely been derived from behavioral therapy. Areas covered: For our update we collected available studies via PubMed searches. This review highlights that already consulting of the patient is able to reduce the frequency of migraine attacks. Relaxation techniques, especially progressive muscle relaxation, and various types of biofeedback are effective, as is the implementation of cognitive behavioral therapy...
September 19, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28885860/anti-lingo-1-opicinumab-a-new-monoclonal-antibody-tested-in-relapsing-remitting-multiple-sclerosis
#7
Serena Ruggieri, Carla Tortorella, Claudio Gasperini
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurodegenerative component or improving mechanism of repair. Areas covered: The latest knowledge about the pathophysiological changes occurring in MS have translated into novel treatments at different stages of development...
September 15, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28885065/recovery-and-serious-mental-illness-a-review-of-current-clinical-and-research-paradigms-and-future-directions
#8
Bethany L Leonhardt, Kelsey Huling, Jay A Hamm, David Roe, Ilanit Hasson-Ohayon, Hamish J McLeod, Paul H Lysaker
Recovery from serious mental illness has historically not been considered a likely or even possible outcome. However, a range of evidence suggests the courses of SMI are heterogeneous with recovery being the most likely outcome. One barrier to studying recovery in SMI is that recovery has been operationalized in divergent and seemingly incompatible ways: as an objective outcome versus a subjective process. Areas covered: This paper offers a review of recovery as a subjective process and recovery as an objective outcome; contrasts methodologies utilized by each approach to assess recovery; reports rates and correlates of recovery; and explores the relationship between objective and subjective forms of recovery...
September 15, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28847182/efficacy-of-antipsychotics-for-irritability-and-aggression-in-children-a-meta-analysis
#9
Gerrit I van Schalkwyk, Alan S Lewis, Chad Beyer, Jessica Johnson, Samuel van Rensburg, Michael H Bloch
BACKGROUND: Aggression and irritability in children occur across a range of diagnoses, and are associated with both economic cost and negative psychosocial outcomes. Antipsychotics are frequently prescribed in these cases. METHODS: A random effects meta-analysis of 14 random controlled trials was conducted. Overall effect sizes for antipsychotics for irritability and aggression were extracted. Subgroup analyses were conducted according to diagnostic indication, specific medication and degree of sedation...
September 11, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28829210/an-update-on-the-recognition-and-treatment-of-non-convulsive-status-epilepticus-in-the-intensive-care-unit
#10
Michael O Kinney, Peter W Kaplan
Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in the field over the last 5-10 years. The articles were selected based on their importance to the field by the authors. Expert commentary: This review discusses the complex situations when a neurological consultation may occur in a critical care setting and provides an update on the latest evidence regarding the recognition of NCSE and the decision making around determining the aggressiveness of treatment...
September 11, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28847186/an-update-on-medications-and-noninvasive-brain-stimulation-to-augment-language-rehabilitation-in-post-stroke-aphasia
#11
Sadhvi Saxena, Argye E Hillis
Aphasia is among the most debilitating outcomes of stroke. Aphasia is a language disorder occurring in 10-30% of stroke survivors. Speech and Language Therapy (SLT) is the gold standard, mainstay treatment for aphasia, but gains from SLT may be incomplete. Pharmaceutical and noninvasive brain stimulation (NIBS) techniques may augment the effectiveness of SLT. Areas covered: Herein reviewed are studies of the safety and efficacy of these adjunctive interventions for aphasia, including randomized placebo-controlled and open-label trials, as well as case series from Pubmed, using search terms 'pharmacological,' 'tDCS' or 'TMS' combined with 'aphasia' and 'stroke...
September 8, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28862482/pseudoprogression-after-glioma-therapy-an-update
#12
Norbert Galldiks, Martin Kocher, Karl-Josef Langen
Initial diagnostics and follow-up of gliomas is usually based on contrast-enhanced MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from posttherapeutic effects such as pseudoprogression is limited. Advanced neuroimaging methods may provide relevant additional information, which allow for a more accurate diagnosis especially in clinically equivocal situations. This review article focuses predominantly on PET using radiolabeled amino acids and advanced MRI techniques such as perfusion-weighted imaging (PWI) and summarizes the efforts of these methods regarding the identification of pseudoprogression after glioma therapy...
September 7, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28854836/medication-overuse-headache-despite-the-advances-in-understanding-it-treatment-evidence-still-lacks
#13
Abouch V Krymchantowski, Carla da Cunha Jevoux
No abstract text is available yet for this article.
September 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28832231/unruptured-intracranial-aneurysms-management-strategy-and-current-endovascular-treatment-options
#14
Laurent Pierot, Matthias Gawlitza, Sébastien Soize
Unruptured intracranial aneurysms (UIA) have a high prevalence (3.2%) and are increasingly diagnosed with modern imaging tools. The main risk of UIA is their rupture associated with intracranial bleeding with often severe clinical consequences. Areas covered: This review discusses the management strategy of UIAs, based on the large series of the literature (ISUIA, ATENA, UCAS, …), knowing that no randomized controlled trial is available to compare different strategies. The different endovascular treatments are described...
September 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28872934/normobaric-hyperoxygenation-a-potential-neuroprotective-therapy-for-acute-ischemic-stroke
#15
Sven Poli, Jean-Claude Baron, Aneesh B Singhal, Florian Härtig
No abstract text is available yet for this article.
September 5, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28845714/the-potential-role-of-cannabinoids-in-epilepsy-treatment
#16
Carmen De Caro, Antonio Leo, Rita Citraro, Caterina De Sarro, Roberto Russo, Antonio Calignano, Emilio Russo
Epilepsy is one of the world's oldest recognized and prevalent neurological diseases. It has a great negative impact on patients' quality of life (QOL) as a consequence of treatment resistant seizures in about 30% of patients together with drugs' side effects and comorbidities. Therefore, new drugs are needed and cannabinoids, above all cannabidiol, have recently gathered attention. Areas covered: This review summarizes the scientific data from human and animal studies on the major cannabinoids which have been of interest in the treatment of epilepsy, including drugs acting on the endocannabinoid system...
September 4, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28832262/long-acting-injectable-antipsychotics-update-lengthening-the-dosing-interval-and-expanding-the-diagnostic-indications
#17
Leslie Citrome
Long-acting injectable (LAI) antipsychotics are a useful but underutilized option in the management of schizophrenia. Areas covered: This is a narrative review of newer LAI antipsychotics approved by the US Food and Drug Administration and is an update to a previously published review from 2013. Emphasized are new indications and new dosing intervals. Expert commentary: Ensuring that persons receiving oral antipsychotics are aware that LAI antipsychotics are available is important. The use of LAI antipsychotics can decrease the risk of relapse in both first-episode and chronic schizophrenia...
September 4, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28829216/leukoaraiosis-as-an-outcome-predictor-in-the-acute-and-subacute-phases-of-stroke
#18
Fabio Fierini, Anna Poggesi, Leonardo Pantoni
Leukoaraiosis (LA) is one of the neuroimaging features of cerebral small vessel disease and is associated with poor long-term prognosis. Areas covered: This narrative review focuses on the predictive role of LA on the evolution of the ischemic brain damage and on the clinical outcome in the subacute phase of stroke and in the short-term period afterwards. Expert commentary: LA predicts poorer tissue outcome and clinical prognosis also in acute and subacute stroke. In acute stroke, LA is associated with a less favorable fate of brain infarct and is a marker of increased risk of thrombolysis-related hemorrhagic transformation...
September 4, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28829200/pharmacological-treatment-of-trigeminal-neuralgia
#19
Giulia Di Stefano, Andrea Truini
Unique among the different neuropathic pain conditions, trigeminal neuralgia frequently has an excellent response to some selected drugs, which, on the other hand, often entail disabling side effects. Physicians should be therefore acquainted with the management of these drugs and the few alternative options. Areas covered: This article, based on a systematic literature review, describes the pharmacological options, and indicates the future perspectives for treating trigeminal neuralgia. The article therefore provides current, evidence-based knowledge about the pharmacological treatment of trigeminal neuralgia, and suggests a practical approach to the various drugs, including starting dose, titration and side effects...
September 4, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28817978/transcutaneous-electrical-nerve-stimulation-tens-as-an-adjunct-for-pain-management-in-perioperative-settings-a-critical-review
#20
Mark I Johnson
Surgical procedures are ever more complex. Day-case surgical loads are increasing and the length of hospital stays are reducing. Management of pain in perioperative settings remains a challenge. Expert panels recommend a multimodal approach which is often interpreted by medical practitioners as polypharmacy. There is variability in non-pharmacological interventions offered to patients, although transcutaneous electrical nerve stimulation (TENS) has been used since the 1970s. Recommendations from expert panels are inconsistent about the use of TENS in perioperative pain settings...
August 24, 2017: Expert Review of Neurotherapeutics
journal
journal
39882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"